Results 121 to 130 of about 46,300 (164)

Research on epicardial adipose tissue as a metabolic therapeutic target in AF: focus on GLP-1 receptor agonists. [PDF]

Front Cardiovasc Med
Liu L, Lu J.
europepmc   +1 more source

GLP-1 receptor agonists and obstructive lung disease: Beyond metabolic control to respiratory outcomes. [PDF]

Metabol Open
Georgakopoulou VE, Dalamaga M.
europepmc   +1 more source

The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications. [PDF]

J Clin Invest
Jalleh RJ, Talley NJ, Horowitz M, Nauck MA.   +3 more
europepmc   +1 more source

Comparative Safety of GLP-1 Receptor Agonists Across Gastrointestinal, Renal and Pancreatic Systems. [PDF]

Pharmaceuticals (Basel)
Shokr H, Mekkawy M, Hindi A.
europepmc   +1 more source

GLP-1 Receptor Agonists - Good for Body Weight, Bad for Micronutrient Status? [PDF]

Curr Dev Nutr
Kerlikowsky F, Krämer K, Eggersdorfer M, Hahn A.   +3 more
europepmc   +1 more source

Interaction Between Metabolic Diseases, GLP-1 Receptor Agonists, and Helicobacter pylori Infection: An Updated Evidence Summary. [PDF]

Korean J Helicobacter Up Gastrointest Res
Lee JY.
europepmc   +1 more source

Psychiatric effects of GLP-1 receptor agonists: A systematic review of emerging evidence. [PDF]

Diabetes Obes Metab
Sa B, Maristany A, Subramaniam A, Guillen R, Buonocore B, Smith A, Oldak SE, Padilla V.   +7 more
europepmc   +1 more source

GLP-1 Receptor Agonists Plus Progestins and Endometrial Cancer Risk in Nonmalignant Uterine Diseases. [PDF]

JAMA Netw Open
Yen TT, Hsieh TYJ, Lee GY, Toy EP, Wei JC, Tanner EJ.   +5 more
europepmc   +1 more source

Informing Hospital Formulary Decisions in China: A Multi-Criteria Value Framework for GLP-1 Receptor Agonists. [PDF]

Risk Manag Healthc Policy
Jiang Y, Qin D, Lin S, Xu X, Wang H.
europepmc   +1 more source